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rise to confusion about drug safety. Risk perception among health 
care professionals and the public differ in many aspects, and so does 
need and quality of drug information. In this presentation, experi-
ence from regional medicines information and pharmacovigilance 
centers in Norway (RELIS) serving health care professionals are 
described. In particular, through a public service started in 2011, 
“SafeMommyMedicine,” RELIS inform pregnant and breastfeeding 
women about risk associated with use of medicines. In parallel with 
this, we focus on research projects in which our service toward both 
target groups is evaluated.
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Summary: By 2014 in the United Kingdom, a system of “value-
based pricing” (VBP) will replace the current Pharmaceutical Price 
Regulation Scheme (PPRS), which is a voluntary agreement between 
the UK Department of Health (DH) and the pharmaceutical indus-
try whereby companies negotiate profit rates from drug sales to the 
National Health Service (NHS) every 5 years. The concept of VBP is 
that prices of individual pharmaceutical products should reflect their 
“clinical and therapeutic value to patients and the broader NHS.” 
This talk describes a potential framework for VBP in the type of 
devolved NHS envisioned in recent UK government reforms. It also 
considers some of the critical features of VBP arrangements that 
need to be appropriately specified if the potential benefits are to be 
realized. The introduction of VBP provides an opportunity to found 
pharmaceutical pricing and access to new health technologies on 
sound principles, reflective of social values and the reality of a budget-
constrained NHS. This requires clarity on key issues of principle and 
social value, as well as critical details of how it will be implemented 
and operate. Any assessment of value must be founded on the type 
of transparent scientific assessment of the costs and benefits offered 
by a technology that is already embodied in the National Institute 
for Health and Care Excellence (NICE) appraisal process. It is also 
important that the assessment of the health expected to be forgone 
elsewhere in the NHS due to additional costs displacing other NHS 
activities (ie, the cost-effectiveness threshold) is evidence based. In 
addition, transparent rules of how prices might be negotiated based 
on such assessments are required.
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Summary: Sjölin-Forsberg, G. and Fluss, S.S.
The Council for International Organizations of Medical Sciences 
(CIOMS) was established by WHO and UNESCO in 1949. One of its 
major objectives has been to contribute to harmonized approaches to 
international systems and terminology used for the safety surveillance 
of medicinal products and vaccines by the publication of consensus 
reports that discuss and recommend general principles. It has hence 
proved crucial to involve experts from drug regulatory authorities, 
research-based biopharmaceutical companies, WHO, academia, and 
public health bodies.
Covered areas of the life cycle of medicinal products have been 
international reporting of adverse drug reactions (the CIOMS I 
reporting form), Adverse Drug Reaction terminology, Standardized 
MedDRA (R) Queries (SMQs), management of safety data from clini-
cal trials, periodic drug safety updates in the pre- and postapproval 
phases, core clinical safety information on drugs under development, 
proposals for harmonized safety information in data sheets or pack-
age inserts, approaches for assessing benefit/risk, pharmacogenetics, 
and pharmacovigilance in resource-limited countries. The 2 most 
recent CIOMS publications cover safety signal detection and man-
agement1 and definition and application of terms for vaccine phar-
macovigilance.2
The ongoing CIOMS Working Group on Practical Considerations 
for Development and Application of a Toolkit for Medicinal Product 
Risk Management has undertaken the challenging task of defining 
fundamental principles that should underlie efforts to minimize or 
mitigate the risks associated with medicines. Risk management also 
involves interaction with health care systems and to increase the 
likelihood of relevance, acceptability, and feasibility of the risk mini-
mization strategy a stakeholder subgroup within Working Group IX 
considered the input from patients, physicians, other HCPs, health 
insurance carriers, and reimbursement bodies.
Meta-analyses and systematic reviews have been increasingly 
used in the scientific evaluation of efficacy and safety for benefit/risk 
assessments, as well as the pricing and reimbursement of biopharma-
ceutical products in clinical practice. CIOMS currently has an ongo-
ing Working Group aimed at developing a consensus on scientific and 
methodological criteria that represent good practices when applied to 
meta-analyses of clinical data within the regulatory process.
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Summary: Lipid-lowering therapy with statins has become the 
cornerstone in the prevention of (recurrent) cardiovascular disease 
(CVD). Statins reduce low-density lipoprotein (LDL)-cholesterol by 
30% to 60% and CVD risk by 25% to 30%. Recent European guide-
lines recommend a LDL-cholesterol goal of < 2.5 mmol/L in patients 
with high CVD risk and even lower in patients with very high risk, 
< 1.8 mmol/L or ≥ 50% reduction in LDL-cholesterol. In patients 
with severe hyperlipidemia as well as in patients who are intolerant of 
statins, these goals cannot be reached. Hence, there is a need for novel 
therapeutic modalities that lower atherogenic lipoproteins in addition 
to statins or alternatively increase protective lipoproteins (HDL).
Several promising new therapeutic approaches have been devel-
oped recently. First, antisense oligonucleotides (ASOs) have been 
proven to be effective in lowering apolipoproteins. ASOs are short 
single strands of DNA that are complimentary in sequence to a seg-
ment of mRNA of specific proteins; after binding to mRNA, trans-
lation and the production of the protein are prevented. The first 
antisense inhibitor of apoB, the structural protein of the atherogenic 
